BR112014003214A2 - polimorfos inibidores de cinase - Google Patents
polimorfos inibidores de cinaseInfo
- Publication number
- BR112014003214A2 BR112014003214A2 BR112014003214A BR112014003214A BR112014003214A2 BR 112014003214 A2 BR112014003214 A2 BR 112014003214A2 BR 112014003214 A BR112014003214 A BR 112014003214A BR 112014003214 A BR112014003214 A BR 112014003214A BR 112014003214 A2 BR112014003214 A2 BR 112014003214A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitor
- polymorphs
- inhibitor polymorphs
- kinase
- inhibitor
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161522624P | 2011-08-11 | 2011-08-11 | |
| PCT/US2012/050453 WO2013023184A1 (en) | 2011-08-11 | 2012-08-10 | Kinase inhibitor polymorphs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014003214A2 true BR112014003214A2 (pt) | 2017-03-14 |
Family
ID=47669006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014003214A BR112014003214A2 (pt) | 2011-08-11 | 2012-08-10 | polimorfos inibidores de cinase |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150065524A1 (enExample) |
| EP (1) | EP2741749A4 (enExample) |
| JP (1) | JP2014521726A (enExample) |
| KR (1) | KR20140079368A (enExample) |
| CN (1) | CN103957918A (enExample) |
| AU (1) | AU2012294202B2 (enExample) |
| BR (1) | BR112014003214A2 (enExample) |
| CA (1) | CA2844742A1 (enExample) |
| CL (1) | CL2014000343A1 (enExample) |
| CO (1) | CO6960542A2 (enExample) |
| CR (1) | CR20140082A (enExample) |
| DO (1) | DOP2014000027A (enExample) |
| EA (1) | EA027970B1 (enExample) |
| EC (1) | ECSP14013236A (enExample) |
| HK (1) | HK1199203A1 (enExample) |
| IL (1) | IL230850A0 (enExample) |
| MX (1) | MX2014001662A (enExample) |
| MY (1) | MY186267A (enExample) |
| PE (1) | PE20141358A1 (enExample) |
| PH (1) | PH12014500331A1 (enExample) |
| RU (1) | RU2636588C2 (enExample) |
| SG (2) | SG10201606288TA (enExample) |
| TN (1) | TN2014000063A1 (enExample) |
| WO (1) | WO2013023184A1 (enExample) |
| ZA (1) | ZA201401211B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1583562T3 (da) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, beslægtede forbindelser og anvendelser deraf |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2740317A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| BRPI0922611A2 (pt) | 2008-12-17 | 2018-11-06 | Angiochem Inc | inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos |
| US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| EP2448965A4 (en) | 2009-07-02 | 2015-02-11 | Angiochem Inc | MULTIMEPEPTID CONJUGATES AND ITS USES |
| US20140377285A1 (en) * | 2011-11-08 | 2014-12-25 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| CN104250250A (zh) * | 2013-06-25 | 2014-12-31 | 苏州科捷生物医药有限公司 | 4-芳香胺基嘧啶类化合物及其抗肿瘤用途 |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| LT3129470T (lt) | 2014-04-07 | 2021-07-12 | Novartis Ag | Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| EP3660042B1 (en) | 2014-07-31 | 2023-01-11 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| AU2015305531B2 (en) | 2014-08-19 | 2021-05-20 | Novartis Ag | Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment |
| KR20250067191A (ko) | 2014-09-17 | 2025-05-14 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| EP3283619B1 (en) | 2015-04-17 | 2023-04-05 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| ES2636646B1 (es) * | 2016-04-05 | 2018-08-03 | Universidade De Santiago De Compostela | NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs |
| EP3487878A4 (en) | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | CAR-T CD229 LYMPHOCYTES AND METHODS OF USE |
| AU2017341047B2 (en) | 2016-10-07 | 2024-10-10 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| WO2018095953A1 (de) | 2016-11-23 | 2018-05-31 | Bayer Cropscience Aktiengesellschaft | 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| BR112020013794B1 (pt) * | 2018-01-09 | 2023-05-02 | Halcyon Labs Private Limited | Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW370529B (en) * | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| PE20180318A1 (es) * | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
-
2012
- 2012-08-10 SG SG10201606288TA patent/SG10201606288TA/en unknown
- 2012-08-10 WO PCT/US2012/050453 patent/WO2013023184A1/en not_active Ceased
- 2012-08-10 CA CA2844742A patent/CA2844742A1/en not_active Abandoned
- 2012-08-10 MX MX2014001662A patent/MX2014001662A/es unknown
- 2012-08-10 CN CN201280043863.6A patent/CN103957918A/zh active Pending
- 2012-08-10 RU RU2014109023A patent/RU2636588C2/ru active
- 2012-08-10 JP JP2014525188A patent/JP2014521726A/ja active Pending
- 2012-08-10 PE PE2014000191A patent/PE20141358A1/es not_active Application Discontinuation
- 2012-08-10 MY MYPI2014000363A patent/MY186267A/en unknown
- 2012-08-10 US US14/238,426 patent/US20150065524A1/en not_active Abandoned
- 2012-08-10 EA EA201490446A patent/EA027970B1/ru not_active IP Right Cessation
- 2012-08-10 BR BR112014003214A patent/BR112014003214A2/pt not_active Application Discontinuation
- 2012-08-10 KR KR1020147006105A patent/KR20140079368A/ko not_active Ceased
- 2012-08-10 EP EP12821708.0A patent/EP2741749A4/en not_active Withdrawn
- 2012-08-10 HK HK14112711.7A patent/HK1199203A1/xx unknown
- 2012-08-10 SG SG2014009492A patent/SG2014009492A/en unknown
- 2012-08-10 AU AU2012294202A patent/AU2012294202B2/en active Active
- 2012-08-10 PH PH1/2014/500331A patent/PH12014500331A1/en unknown
-
2014
- 2014-02-06 IL IL230850A patent/IL230850A0/en unknown
- 2014-02-10 DO DO2014000027A patent/DOP2014000027A/es unknown
- 2014-02-11 CL CL2014000343A patent/CL2014000343A1/es unknown
- 2014-02-11 TN TNP2014000063A patent/TN2014000063A1/en unknown
- 2014-02-18 ZA ZA2014/01211A patent/ZA201401211B/en unknown
- 2014-02-20 CR CR20140082A patent/CR20140082A/es unknown
- 2014-03-11 EC ECSP14013236 patent/ECSP14013236A/es unknown
- 2014-03-11 CO CO14051879A patent/CO6960542A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012294202A1 (en) | 2014-03-06 |
| CR20140082A (es) | 2014-06-03 |
| KR20140079368A (ko) | 2014-06-26 |
| EA201490446A1 (ru) | 2014-05-30 |
| MX2014001662A (es) | 2014-08-26 |
| SG2014009492A (en) | 2014-09-26 |
| NZ622208A (en) | 2016-04-29 |
| SG10201606288TA (en) | 2016-09-29 |
| ECSP14013236A (es) | 2014-06-30 |
| TN2014000063A1 (en) | 2015-07-01 |
| US20150065524A1 (en) | 2015-03-05 |
| RU2014109023A (ru) | 2015-09-20 |
| IL230850A0 (en) | 2014-03-31 |
| MY186267A (en) | 2021-07-01 |
| EP2741749A1 (en) | 2014-06-18 |
| EP2741749A4 (en) | 2015-04-15 |
| CL2014000343A1 (es) | 2014-10-17 |
| ZA201401211B (en) | 2015-12-23 |
| PE20141358A1 (es) | 2014-10-12 |
| JP2014521726A (ja) | 2014-08-28 |
| EA027970B1 (ru) | 2017-09-29 |
| RU2636588C2 (ru) | 2017-11-24 |
| DOP2014000027A (es) | 2014-07-15 |
| CA2844742A1 (en) | 2013-02-14 |
| CO6960542A2 (es) | 2014-05-30 |
| WO2013023184A1 (en) | 2013-02-14 |
| CN103957918A (zh) | 2014-07-30 |
| AU2012294202B2 (en) | 2017-02-23 |
| PH12014500331A1 (en) | 2014-03-31 |
| HK1199203A1 (en) | 2015-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1006I1 (fr) | Inhibiteurs de pyrazolyl-quinoxaline kinase | |
| BR112014003214A2 (pt) | polimorfos inibidores de cinase | |
| EP2710007A4 (en) | Kinase inhibitors | |
| CO6970602A2 (es) | Inhibidores de quinasa | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| LT3181567T (lt) | Pirazolpirimidino junginiai kaip kinazės slopikliai | |
| CO6950481A2 (es) | Inhibidores de proteínas quinasas | |
| HUE047888T2 (hu) | Glükozilceramid-szintáz-inhibitor | |
| CO6900145A2 (es) | Compuesto de ciclopropanoamina | |
| HRP20181786T1 (hr) | Inhibitori aktivacije t-stanica | |
| HRP20181533T1 (hr) | Antikancerogeni piridopirazini putem inhibitora fgfr kinaze | |
| EP2684880A4 (en) | DISPIROPYRROLIDINDERIVAT | |
| CR20130231A (es) | Compuestos antivirales | |
| BR112014007781A2 (pt) | compostos anti-virais | |
| EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
| IL230561A0 (en) | Inhibitors of bruton's tyrosine kinsae | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| BR112014012016A2 (pt) | compostos | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| CO6910197A2 (es) | Compuestos novedosos | |
| SMT201600328B (it) | Nuovi composti come inibitori di diacilglicerolo aciltransferasi | |
| EP2776428A4 (en) | KINASEHEMMERPOLYMORPHE | |
| IL228567A0 (en) | Imidazopyridazines as akt kinase inhibitors | |
| CO6990735A2 (es) | Inhibidores de pirazina cinasa | |
| CO6960557A2 (es) | Derivados de 2-yodo-imidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |